Table 5: Key eligibility criteria for reimbursement of paritaprevir-ritonavir-ombitasvir plus dasabuvir (with or without ribavirin) for treatment of hepatitis C virus infection, by jurisdiction
Minimum fibrosis stage requiredSubstance useHIV coinfectionPrescriberDecompensated cirrhosis
British ColumbiaF2None listed*EligibleGeneral practitionerNone listed
AlbertaF2None listedEligibleGeneral practitionerIneligible
SaskatchewanF2None listed†EligibleGeneral practitionerIneligible
ManitobaF2None listedEligibleSpecialistIneligible
OntarioF2None listedEligibleGeneral practitionerIneligible
QuebecF3‡None listedEligible§General practitionerIneligible
New BrunswickF2None listedEligibleGeneral practitionerIneligible
Nova ScotiaF2None listedEligibleSpecialistIneligible
Prince Edward IslandNo restrictionsNone listed¶Eligible**General practitionerNone listed
Newfoundland and LabradorF2None listedEligibleGeneral practitionerIneligible
YukonF2None listedEligibleSpecialistIneligible
Northwest TerritoriesF2None listedNone listedNone listedNone listed
NunavutF2None listedNone listedNone listedNone listed
Non-Insured Health Benefits ProgramF2None listedNone listedNone listedNone listed
Correctional Service CanadaF2††None listedNone listedNone listedNone listed

*No specific criteria, but exclusion criteria stated: "Patients who are at high risk for non-compliance."

†However, prescriber could indicate that directly observed therapy was recommended; also, the patient consented (via signature) to understanding treatment adherence.

‡In year 1 (2015/16), only those with stage F3 or F4 fibrosis received reimbursement.

§Treated in year 1 if stage F3 or F4 fibrosis.

¶There were restrictions (e.g., active injection drug use) left to physician's discretion.

**Must be treated by a specialist off-island.

††Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.